Sema4 Elements™

Data-driven reproductive & generational health solutions

Solutions for the whole journey

Sema4 Elements offers a portfolio of information-driven genomic solutions, digital tools, and services that enable providers to treat patients holistically during their reproductive and generational health journey. Today, we offer gold-standard testing for carrier screening, noninvasive prenatal testing, and newborn screening, as well as hereditary cancer testing.

Pregnant Icon

Reproductive

Expanded Carrier Screen

One of the most comprehensive carrier screens available, providing accurate, actionable insights into carrier status for a broad range of hereditary conditions to help patients make more informed pregnancy planning choices. Learn more about the benefits of our latest offering.

Noninvasive Prenatal Select

Comprehensively screens for common chromosome aneuploidies, sex chromosome aneuploidies, and microdeletion syndromes, with the flexibility to order select components of the test. Learn more.

Post Natal Icon

Post Natal

Natalis Supplemental Newborn Screen

Detects 193 childhood conditions, many of which can’t be detected by carrier screening, standard prenatal tests, or state newborn screening alone. Also includes a pharmacogenomic (PGx) analysis of a child’s response to more than 40 medications that may be prescribed during childhood, including common antibiotics. Learn more.

Preventative Icon

Preventative

Hereditary Cancer

Offers a menu of panels to help you and your patients understand their individual risk for developing cancer or to inform treatment decisions. These tests are enabled through a set of digital tools and services to support easy identification, ordering, resulting, counseling, and access to testing. Learn more.

Unparalleled support

We understand the complexity that comes with navigating the world of genetics and genomics – including test ordering, billing, insurance coverage, genetic counseling, and reporting of results – and offer services and digital tools to support you, your practice, and your patients.

Support for providers

  • High-quality reproductive and hereditary cancer tests and services to support you and your patients
  • Dedicated Customer Success team
  • Personalized services to seamlessly align with your practice workflow
  • Digital tools, such as the Sema4 Provider Portal, to make it easy for you to order and review test results, access detailed test information, and interface with your EMR
  • Genetic counseling services for your patients and your practice to offer education, assistance interpreting results, and guidance on care options

Support for patients

  • In-network with the majority of national and regional insurers. we also accept both Medicaid and Medicare and are dedicated to helping providers and patients navigate the billing landscape
  • Patient-friendly billing policies, including competitive self-pay prices and financial assistance programs
  • We appeal coverage determinations on behalf of patients if precertification or pre-authorization requests are denied
  • Patients can track their tests, view results, and access educational materials through the Sema4 Patient Portal

Pregnancy Journey

A digital, educational resource tool available exclusively via our Patient Portal designed to help patients learn about developmental changes to expect during their pregnancy, with the option to track their vitals. Learn more.

 

Sema4 helped a family who was originally
told their infant daughter had Gaucher disease.

 

“We were so relieved. Sema4 really went above and beyond in
terms of investigating this and tracking down the truth.”

– Michael, father of infant daughter

 

Solutions along the continuum of care

 

*Prenatal molecular and biochemical testing is available for every disease on our Expanded Carrier Screening
panel along with any additional testing required to support that pregnancy.

 

Start the Journey with Us

Kindly fill out the form below and we’ll schedule a time to discuss your needs. Or feel free to call us at 800-298-6470.